Inactive Instrument

Satsuma Pharmaceuticals, Inc.

STSA

US80405P1075

Biotechnology & Medical Research

Satsuma Pharmaceuticals, Inc. Announces CEO Changes

June 08, 2023 at 09:13 am EDT

Satsuma Pharmaceuticals, Inc. announced that Upon completion of the Merger on June 8, 2023, John Kollins ceased serving as Chief Executive Officer of the Company.

Latest news about Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration	Jan. 17	CI
Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from NASDAQ Composite Index	23-06-09	CI
Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from S&P TMI Index	23-06-09	CI
Insider Buy: Satsuma Pharmaceuticals	23-06-08	MT
Satsuma Pharmaceuticals, Inc. Announces CFO Changes	23-06-08	CI
Satsuma Pharmaceuticals, Inc. Announces CEO Changes	23-06-08	CI
Satsuma Pharmaceuticals, Inc. Announces Board Changes	23-06-08	CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.	23-06-07	CI
Satsuma Pharmaceuticals' New Drug Application for Migraine Treatment Accepted for FDA Review	23-05-18	MT
Satsuma Pharmaceuticals, Inc. Announces FDA Acceptance of 505(b)(2) New Drug Application for STS101	23-05-18	CI
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
North American Morning Briefing : Sentiment -3-	23-04-19	DJ
HC Wainwright Downgrades Satsuma Pharmaceuticals to Neutral From Buy	23-04-18	MT
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals	23-04-18	MT
Sector Update: Health Care Stocks Higher Premarket Monday	23-04-17	MT
Bank Earnings in Focus as US Equity Futures Tread Water	23-04-17	MT
Top Premarket Gainers	23-04-17	MT
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical	23-04-17	MT
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million.	23-04-16	CI
Satsuma Pharmaceuticals Cash, Cash Equivalents and Marketable Securities Almost Halve to $52.5 Million at End of 2022	23-03-28	MT
Satsuma Pharmaceuticals Implements 36% Reduction in Workforce as Part of Cost-Cutting Program Shares Fall After Hours	23-03-28	MT
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-28	CI
Satsuma Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-27	CI
North American Morning Briefing : Stock Futures -3-	23-03-27	DJ

Chart Satsuma Pharmaceuticals, Inc.

Duration

Period

More charts

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapeutic product for the acute treatment of migraine. The Company's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.29B
ARGENX SE	+2.13%	22.18B
BIONTECH SE	-15.84%	21.2B
GENMAB A/S	-9.21%	18.31B
WUXI APPTEC CO., LTD.	-39.98%	17.38B
BEIGENE, LTD.	-14.65%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.97B
SAREPTA THERAPEUTICS, INC.	+31.35%	12.17B

Bio Therapeutic Drugs